← All Pulmatrix, INC filings

Pulmatrix, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PULM
Pulmatrix, INC
10-K/A: Pulmatrix Amends 10-K, Awaits Cullgen Merger Approval
Pulmatrix, Inc. filed an amended annual report to correct a typographical error and provided updated financial statements showing reduced operating expenses and net loss, while awaiting critical regulatory approval for its merger with Cullgen Inc.
NASDAQ
PULM
Pulmatrix, INC
10-K: Pulmatrix Pivots to Cullgen Merger, Halts Drug Development
Pulmatrix is shifting its strategic focus to a merger with Cullgen Inc., pausing all internal drug development while seeking to monetize its existing iSPERSE-based assets.
NASDAQ
PULM
Pulmatrix, INC
10-K: Pulmatrix, Inc. Navigates Strategic Review and Merger Plans Amidst Financial Realities
Pulmatrix, Inc. outlines its strategic review process, merger agreement with Cullgen Inc., and financial results for the year ended December 31, 2024, highlighting ongoing efforts to monetize clinical assets and manage financial challenges.
NASDAQ
PULM
Pulmatrix, INC
10-K: Pulmatrix, Inc. Reports Full Year 2023 Results, Provides Pipeline Update
Pulmatrix, Inc. released its 2023 annual report, detailing financial results and progress on its inhaled therapeutic pipeline, including updates on PUR3100, PUR1800, and PUR1900.